giredestrant: Clinical Trials

9 trials of giredestrant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 active not recruiting, 3 recruiting, 1 not yet recruiting. 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 39Active not recruiting 5, Recruiting 3, Not yet recruiting 1

Follow giredestrant: new trials by email Literature Review of giredestrant trials Research Report on giredestrant

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
Phase 3Not yet recruitingPfizer38002026-12-012026-11-10
A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
Giredestrant - Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer
Phase 3RecruitingHoffmann-La Roche15002026-11-302026-11-12
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Giredestrant - Early Breast Cancer
Phase 3RecruitingGenentech, Inc.3002026-08-252026-11-12
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Giredestrant, Fulvestrant, Abemaciclib - Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Phase 3Active not recruitingHoffmann-La Roche10502023-12-112026-09-14
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Ipatasertib, Tiragolumab, Atezolizumab - Cancer
Phase 3RecruitingHoffmann-La Roche2002023-06-012026-11-06
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Giredestrant, Exemestane, Fulvestrant - Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Phase 3Active not recruitingGenentech, Inc.3732022-08-032026-11-03
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Phesgo, Giredestrant, Docetaxel - Locally Advanced or Metastatic Breast Cancer
Phase 3Active not recruitingHoffmann-La Roche9222022-07-182026-10-02
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist - Early Breast Cancer
Phase 3Active not recruitingHoffmann-La Roche41702021-08-272026-10-15
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Giredestrant, Giredestrant-matched Placebo, Letrozole - Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Phase 3Active not recruitingHoffmann-La Roche9922020-10-092026-11-12

Conditions studied

Breast Neoplasms (7)  ·  Neoplasms (1)

Sponsors

Hoffmann-La Roche (6)  ·  Genentech, Inc. (2)  ·  Pfizer (1)

Countries

United States (7)  ·  South Korea (6)  ·  Taiwan (6)  ·  Argentina (5)  ·  Belgium (5)  ·  Canada (5)  ·  China (5)  ·  France (5)  ·  Germany (5)  ·  Greece (5)  ·  Italy (5)  ·  Mexico (5)  ·  Poland (5)  ·  Spain (5)  ·  Thailand (5)

Results publications

PMID 38789924, PMID 42814929

NIH funding

2023 (4)